Active	Status	Sponsor type	Region	Phase	Filter
19 Active 0 Inactive 19 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

19 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mullinax, Karen
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Recruiting	3	14000	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	03/29	03/29
Thompson, Ernest
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD	Recruiting	3	400	US	TQJ230, pelacarsen, Placebo	Novartis Pharmaceuticals	Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease	03/27	03/27
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia	Recruiting	3	1328	Canada, US	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Hypertriglyceridemia	07/26	10/26
SHASTA-4, NCT06347016: Study of Plozasiran in Adults With Severe Hypertriglyceridemia	Recruiting	3	300	Canada, US	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Severe Hypertriglyceridemia	07/26	10/26
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease	Active, not recruiting	3	9541	Europe, Canada, Japan, US, RoW	Obicetrapib, Placebo	NewAmsterdam Pharma, Monash University	Atherosclerotic Cardiovascular Disease	11/26	11/26
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease	Active, not recruiting	3	17004	Europe, Canada, Japan, US, RoW	Inclisiran sodium 300 mg, Placebo	Novartis Pharmaceuticals	Atherosclerotic Cardiovascular Disease	10/27	10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Recruiting	3	14000	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	03/29	03/29
Ganji, Jagadeesh
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Overweight and Obesity	02/29	02/29
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease	Active, not recruiting	3	9541	Europe, Canada, Japan, US, RoW	Obicetrapib, Placebo	NewAmsterdam Pharma, Monash University	Atherosclerotic Cardiovascular Disease	11/26	11/26
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Recruiting	3	14000	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	03/29	03/29
LUX-Dx TRENDS, NCT04790344: Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.	Active, not recruiting	N/A	525	US	Investigational LUX-Dx ICM Implant	Boston Scientific Corporation	Heart Failure	05/26	06/26
Messina, Tina
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Recruiting	3	14000	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	03/29	03/29
Frost, Theresa
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Recruiting	3	14000	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	03/29	03/29
Vedre, Ameeth
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Recruiting	3	14000	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	03/29	03/29
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure	Active, not recruiting	2	136	Europe, Japan, US, RoW	Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan	Novartis Pharmaceuticals	Heart Failure	10/25	12/25
NCT05562934: An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.	Completed	2	194	Europe, Japan, US, RoW	Experimental drug, Placebo	Novartis Pharmaceuticals	Resistant Hypertension	07/24	08/24
DETECT-HF, NCT06378632: AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM	Recruiting	N/A	500	US, RoW	Hearo App	Cordio Medical	Heart Failure	07/24	12/24
Ducote, Rosina
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Recruiting	3	14000	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	03/29	03/29